IO Biotech Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.42
- Today's High:
- $1.73
- Open Price:
- $1.69
- 52W Low:
- $1.42
- 52W High:
- $3.52
- Prev. Close:
- $1.671
- Volume:
- 763391
Company Statistics
- Market Cap.:
- $119.24 million
- Book Value:
- 3.627
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -31.66%
- Return on Equity TTM:
- -53.47%
Company Profile
IO Biotech Inc had its IPO on 2021-11-05 under the ticker symbol IOBT.
The company operates in the Healthcare sector and Biotechnology industry. IO Biotech Inc has a staff strength of 57 employees.
Stock update
Shares of IO Biotech Inc opened at $1.69 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.42 - $1.73, and closed at $1.45.
This is a -13.23% slip from the previous day's closing price.
A total volume of 763,391 shares were traded at the close of the day’s session.
In the last one week, shares of IO Biotech Inc have slipped by -19.89%.
IO Biotech Inc's Key Ratios
IO Biotech Inc has a market cap of $119.24 million, indicating a price to book ratio of 0.5238 and a price to sales ratio of 0.
In the last 12-months IO Biotech Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-75843000. The EBITDA ratio measures IO Biotech Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, IO Biotech Inc’s operating margin was 0% while its return on assets stood at -31.66% with a return of equity of -53.47%.
In Q2, IO Biotech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
IO Biotech Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.58 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into IO Biotech Inc’s profitability.
IO Biotech Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.945. Its price to sales ratio in the trailing 12-months stood at 0.
IO Biotech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $117.56 million
- Total Liabilities
- $10.88 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $39000
- Dividend Payout Ratio
- 0%
IO Biotech Inc ended 2024 with $117.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $117.56 million while shareholder equity stood at $104.52 million.
IO Biotech Inc ended 2024 with $0 in deferred long-term liabilities, $10.88 million in other current liabilities, 29000.00 in common stock, $-215961000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $110.10 million and cash and short-term investments were $110.10 million. The company’s total short-term debt was $613,000 while long-term debt stood at $0.
IO Biotech Inc’s total current assets stands at $113.04 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.20 million compared to accounts payable of $4.46 million and inventory worth $929000.00.
In 2024, IO Biotech Inc's operating cash flow was $0 while its capital expenditure stood at $39000.
Comparatively, IO Biotech Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.45
- 52-Week High
- $3.52
- 52-Week Low
- $1.42
- Analyst Target Price
- $10
IO Biotech Inc stock is currently trading at $1.45 per share. It touched a 52-week high of $3.52 and a 52-week low of $3.52. Analysts tracking the stock have a 12-month average target price of $10.
Its 50-day moving average was $1.85 and 200-day moving average was $2.2 The short ratio stood at 4.11 indicating a short percent outstanding of 0%.
Around 640.3% of the company’s stock are held by insiders while 7784.5% are held by institutions.
Frequently Asked Questions About IO Biotech Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company’s lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.